On the other hand, as HGSOC represents the most prevalent and aggressive subtype of ovarian cancers that are approved for clinical use of PARP inhibitors, our study purposedly chose ovarian cancer cell line models featuring genomic profiling of HGSOC, including SNU119, OVSAHO, COV362 and OVCAR4 (44). This evidence concerns the gene PARP1 and ovarian carcinoma.